.

Gilead Sciences reported $242M in Interest Expense on Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
ALKERMES ALKS:US 2.37M 19K
Alnylam Pharmaceuticals ALNY:US $ 42.61M 247K
Amgen AMGN:US $ 328M 33M
Biogen BIIB:US $ 65.8M 0.3M
Biomarin Pharmaceutical BMRN:US $ 3.86M 0.05M
Bristol Myers Squibb BMY:US $ 313M 13M
Eli Lilly And LLY:US $ 81.2M 3.7M
Gilead Sciences GILD:US $ 242M 4M
Intercept Pharmaceuticals ICPT:US $ 6.67M 0M
Moderna Inc MRNA:US 5M 1000K
Neurocrine Biosciences NBIX:US $ 2.2M 0.4M
Novartis NOVN:VX 202M 1000K
Pfizer PFE:US $ 293M 29M
Ptc Therapeutics PTCT:US $ 22.28M 1.34M
Puma Biotechnology PBYI:US $ 2.7M 0.04M
Regeneron Pharmaceuticals REGN:US $ 13.1M 0.5M
Sarepta Therapeutics SRPT:US $ 16.03M 0.23M
Teva Pharmaceutical Industries TEVA:US $ 225M 13M
United Therapeutics UTHR:US $ 6.2M 1.5M
Vertex Pharmaceuticals VRTX:US $ 14.6M 0.3M
YTE INCY:US $ 0.68M 0M